Pfizer investor relations contact
This release contains forward-looking information about a global license agreement between Pfizer and Theravance Biopharma, and Theravance Biopharma's program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Find the latest SEC Filings data for Pfizer, Inc. Common Stock (PFE) at Nasdaq.com. Looking for additional market data? Investor Relations Contact Careers Advertise Nasdaq MarketSIte If you require a printed copy of the Annual Report, please write to us at contactus.india@pfizer.com with your membership details. Go to Top Results :